New hope for Tough-to-Treat leukemia: experimental drug combo enters testing
NCT ID NCT05780879
Summary
This study is testing whether adding a drug called venetoclax to a standard chemotherapy regimen (FLAG or CLAG) is more effective for treating newly diagnosed secondary acute myeloid leukemia (sAML). The main goal is to see if this combination helps more patients achieve complete remission. The trial will enroll about 20 adults with sAML who have not received prior treatment for this specific condition.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SECONDARY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
Conditions
Explore the condition pages connected to this study.